

Substitute for form 1449A/B/PTO				Complete if Known	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/527,707-Conf. #5292
				Filing Date	March 11, 2005
				First Named Inventor	Ravi Acharya
				Art Unit	1792
				Examiner Name	R. M. Kunemund
Sheet	1	of	1	Attorney Docket Number	30699/41065

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	B1	EP-0444605	09-04-1991	Unitika Ltd.		
	B2*	WO-1991/00354	01-10-1991	Inst. Nat. Sante Rech. Med		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ Applicant is to place a check mark here if English language Translation is attached. CITE NO An English language abstract of the document which is marked with an asterisk (*) next to the Cite No. is supplied herewith.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	BROWN et al., Structure of neurolysin reveals a deep channel that limits substrate access. <i>Proc. Natl. Acad. Sci. USA</i> 98: 3127-32 (2001).	
	C2	GORDON et al., Deglycosylation, processing and crystallization of human testis angiotensin-converting enzyme. <i>Biochem. J.</i> 271: 437-42 (2003).	
	C3	GSCHWEND et al., Molecular docking towards drug discovery, <i>J. Molec. Rec.</i> 9: 175-86 (1996).	
	C4	KIM et al., Crystal structure of Drosophila angiotensin I-converting enzyme bound to captopril and lisinopril. <i>FEBS Lett.</i> 538: 65-70 (2003).	
	C5	LIU et al., Arg-1098 is critical for the chloride dependence of human angiotensin-1 converting enzyme C-domain catalytic activity. <i>J. Biol. Chem.</i> 276: 33518-25 (2001).	
	C6	NATESH et al., Crystal structure of the human angiotensin-converting enzyme-lisinopril complex. <i>Nature</i> 421: 551-4 (2003).	
	C7	NATESH et al., Database Protein Data Bank, Crystal structure of humane ACE (native), February 7, 2003.	
	C8	TARENTINO et al., Enzymatic deglycosylation of asparagine-linked glycans: purification, properties, and specificity of oligosaccharide-cleaving enzymes from Flavobacterium meningosepticum. <i>Methods Enzymol.</i> 230: 44-57 (1994).	
	C9	WHITTLE et al., Protein structure-based drug design annual review of biophysics and biomolecular structure. Annual Reviews Inc. Palo Alto, CA. 23: 349-75 (1994).	
	C10	International Search Report, European Patent Office, PCT/GB2003/03966, dated February 25, 2004.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--